- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05776095
Evaluation of Safety and Performance Outcomes of Eyedeal IOL Implantation After Cataract Removal
A Prospective, Multicenter Study to Evaluate Safety and Performance Outcomes of Eyedeal Intraocular Lens Implantation After Cataract Removal
A cataract is the clouding of the natural lens in the eye and is very common as when getting older. A cloudy lens makes it difficult to see. A cataract is treated by removing the cloudy lens and replacing it with an intraocular lens (known as an IOL). The goal of this clinical trial is to determine if the Eyedeal® IOL can be safely implanted in a subject's eye and if it can replace efficiently the natural lens.
Subjects will be asked to attend a total of seven visits for this study for a period of 12 months after surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To investigate the safety and performance of the Eyedeal® PX65AS1 intraocular lens (IOL)
- To evaluate the safety profile with regards to best-corrected visual acuity, and adverse events
- To evaluate the performance with regards of best corrected distance VA after the device implantation
The Eyedeal® IOL (PX65AS1) is a foldable single-piece ultra-violet absorbing posterior chamber intraocular lens (IOL). It is an optical implant to replace the human crystalline lens in the visual correction of aphakia in adult patients after cataract removal. The Eyedeal® PX65AS1 IOL lens is made of a high refractive index soft cross-linked polyolefin. The Eyedeal® PX65AS1 IOL lens has an aspheric optic with symmetric optic design and spherical neutral and correct lens's own spherical aberration supporting haptics to provide proper position of the IOL optic within the capsule.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Q. Trin Peng, MD
- Phone Number: +86 029 848 88888
- Email: info@eyedeal.com
Study Locations
-
-
Baden-Wuerttemberg
-
Heidelberg, Baden-Wuerttemberg, Germany, 69120
- Not yet recruiting
- University Eye Clinic Heidelberg
-
Contact:
- Raquel Willrich Amroussi, MA
-
Principal Investigator:
- Prof. Dr. med. Gerd U. Auffarth, MD PHD
-
-
-
-
-
Kaunas, Lithuania, 50161
- Recruiting
- Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences Kauno klinikos
-
Contact:
- Eglė Karinauskė, MD
-
Principal Investigator:
- Prof. Reda Žemaitienė, MD, PHD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (22 years of age or older at the time of surgery) of any gender and race, diagnosed with age related cataracts in one eye.
- Preoperative best corrected distance visual acuity (BCDVA) of 20/32 or worse.
- Projected postoperative BCDVA 0.20 logMAR or better in the study eye, as determined by Investigator's medical judgment.
- Calculated spherical power targeted at emmetropia at distance in the study eye.
- Calculated lens power within the available range for the Eyedeal® Model PX65AS1 IOL (+0.50D - +34.00D).
- Planned cataract removal by phacoemulsification procedure.
- Clear intraocular media other than cataract, in the study eye.
- Pharmacologically dilated pupil size of at least 6.0mm.
- 2.0 D or less of preoperative astigmatism in the study eye.
- Willing and able to complete all required postoperative visits.
- Able to comprehend and sign or through a representative, with a witness present, a statement of IRB or EC approved Informed Consent Form (ICF).
Exclusion Criteria:
- Any type of cataract (e.g., traumatic, congenital, polar) other than those noted in inclusion criteria.
- Ocular conditions which could affect the stability of the IOL (e.g., pseudoexfoliation, zonular dialysis, evident zonular weakness or dehiscence, etc.) in the study eye.
- Any anterior segment pathology likely to increase the risk of complications from phacoemulsification cataract extraction (e.g., chronic uveitis, iritis, iridocyclitis, aniridia, rubeosis iridis, clinically significant corneal disorders, (Fuch's, or anterior basement membrane dystrophy, etc.) in the study eye.
- Mature cataract that is likely to prolong phacoemulsification and/or lead to intraoperative complications prior to attempted IOL implantation.
- Any visually significant intraocular media opacity other than cataract in the study eye.
- History of any clinically significant retinal pathology or ocular diagnosis (e.g., diabetic retinopathy, ischemic disease, macular degeneration, retinal detachment, amblyopia, optic neuropathy, microphthalmos, aniridia, neuro-ophthalmic disease, fixation problems etc.) in the study eye that could alter or limit final postoperative visual prognosis.
- History of any intraocular, retinal, corneal or refractive surgery in the study eye (including LASIK, PRK, LRI, etc.).
- History of cystoid macular edema in the study eye.
- History of serious corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.) in either eye.
- Severe dry eye that, in the opinion of the investigator, would impair the ability to obtain reliable study measurements.
- Uncontrolled glaucoma and/or optic atrophy in the study eye.
- Subjects with large refractive errors (hyperopia/myopia) of axial or pathologic origin that, in the opinion of the investigator, could confound outcomes.
- Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or irregular astigmatism).
- Uncontrolled systemic disease (e.g., diabetes mellitus, active cancer treatment, mental illness, etc.) in the opinion of the investigator, would put the subject's health at risk and/or prevent the subject from completing all study visits.
- Systemic medication that, in the opinion of the investigator, may confound the outcome or increase the intraoperative and post-operative risk to the subject (e.g., tamsulosin hydrochloride) or other medications including anticholinergics, alpha adrenergic blocking agents with similar side effects (e.g., small pupil/floppy iris syndrome).
- Subjects who may reasonably be expected to require any additional ophthalmic surgical intervention at any time during the study (other than YAG capsulotomy).
- Need for concomitant procedures (e.g., glaucoma surgery, LRI, RK, LASIK, etc.).
- Fellow eye BCDVA worse than 1.0 logMAR.
- Extremely shallow anterior chamber (< 2.0 mm).
- Participation in any other drug or device clinical trial within 30 days prior to enrolling this study and/or during study participation.
- Pregnancy or lactation.
- Subject who, in the judgment of the clinical investigator, is not suitable for participation in the study for any clinical reason, as documented by the investigator on the patient's Case Report Forms - CRFs).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eyedeal® IOL
Eyedeal® Model PX65AS1 IOL
|
Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EFFICACY OUTCOME MEASURE - Uncorrected Distance Visual Acuity
Time Frame: 12 months
|
Uncorrected distance Visual Acuity is measured in accordance with ISO 11979-7:2018 - Appendix E: BCVA 20/40 or better in 95% of cases.
The stability and consistency of visual results will be measured over time.
|
12 months
|
SAFETY OUTCOME MEASURE - Best Corrected Visual Acuity
Time Frame: 12 months
|
The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Loss of BCDVA measured in accordance with ISO 11979-7:2018-Appendix E |
12 months
|
SAFETY OUTCOME MEASURE - Evaluation of Patient record
Time Frame: 12 months
|
The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Patient record of inflammation, discomfort, or pain following surgery related to the Eyedeal® Model PX65AS1 IOL (Xi'an Eyedeal Medical Technology Co., Ltd.) . . |
12 months
|
SAFETY OUTCOME MEASURE - Evaluation of Adverse Events
Time Frame: 12 months
|
The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Evaluation of all adverse events, adverse device effects and device deficiencies at post-operative examinations |
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gerd Auffarth, Prof, University Eye Clinic Heidelberg
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EU-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lens Implantation, Intraocular
-
Eyebright Medical Technology (Beijing) Co., Ltd.CompletedIntraocular Lens Implantation
-
Yuzuncu Yıl UniversityVSY BiotechnologyRecruitingCataract | Lens Implantation, IntraocularTurkey
-
University of Southern CaliforniaAlcon ResearchWithdrawnCataract | Intraocular Lens Implantation
-
Rabin Medical CenterEinat Medical Inc.UnknownRefractive Error | Corneal Implantation | Intraocular Lens ImplantationIsrael
-
Maastricht University Medical CenterCompletedVisual Acuity | Pseudophakia | Cataract Bilateral | Lens, Intraocular | Lens Implantation, IntraocularNetherlands
-
Instituto de Oftalmología Fundación Conde de ValencianaRecruitingCataract | Humans | Intraocular Lens Implantation | Ocular, RefractionMexico
-
Wenzhou Medical UniversityRecruitingCongenital Cataract | Intraocular Lens Implantation | Optic CaptureChina
-
University of Sao PauloCompletedLens Implantation, IntraocularBrazil
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruitingLens Implantation, IntraocularChina
-
Peking University Third HospitalCompletedAdolescent | Myopia | Female | Adult | Male | Preoperative Period | Lens Implantation, Intraocular | Tomography, Optical Coherence | Postoperative Period | Human | Prospective Studies | Follow-up Studies | Phakic Intraocular Lenses | Retinal VesselsChina
Clinical Trials on Cataract surgery
-
Iladevi Cataract and IOL Research CenterCompletedCataract Surgery | Shallow Anterior Chamber | PhacoemulsificationIndia
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
University of OklahomaCompletedPrimary Open Angle Glaucoma | Cataract | Pigmentary GlaucomaUnited States
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
Glaukos CorporationCompletedOpen-Angle GlaucomaUnited States
-
Ziemer Ophthalmic Systems AGRecruiting
-
Technolas Perfect Vision GmbHCompleted
-
Sun Yat-sen UniversityCompleted
-
Guy's and St Thomas' NHS Foundation TrustCompletedCataract | Surgery
-
University Hospital, BordeauxCompleted